Third, pharmacologic regimens should align evidence-based HF therapies (e.g., ACE inhibitors, beta-blockers) with glucose-lowering agents that confer cardiovascular benefits, such as SGLT2 inhibitors or GLP-1 receptor agonists, while considering renal safety and comorbidities [3,84]. This evidence concerns the gene GLP1R and hydrops fetalis.